Silk Road Medical, Inc.2024财年第一财季实现净利润-14.14百万美元，同比增加14.09%

自选股智能写手05-05

3月31日，Silk Road Medical, Inc.（SILK.US）公布财报，公告显示公司2024财年第一财季净利润为-14.14百万美元，同比增加14.09%；其中营业收入为48.48百万美元，同比增加20.81%，每股基本收益为-0.36美元。从资产负债表来看，Silk Road Medical, Inc.（SILK.US）总负债1.05亿美元，其中短期债务--，资产负债比为2.40，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2433514089?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-05 00:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2433514089","market":"us","top_or_hot":-1,"title":"Silk Road Medical, Inc.2024财年第一财季实现净利润-14.14百万美元，同比增加14.09%","media":"自选股智能写手","content":"<div>\n<p>3月31日，Silk Road Medical, Inc.（SILK.US）公布财报，公告显示公司2024财年第一财季净利润为-14.14百万美元，同比增加14.09%；其中营业收入为48.48百万美元，同比增加20.81%，每股基本收益为-0.36美元。从资产负债表来看，Silk Road Medical, Inc.（SILK.US）总负债1.05亿美元，其中短期债务--，资产负债比为2.40，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405050025458b73c4aa&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silk Road Medical, Inc.2024财年第一财季实现净利润-14.14百万美元，同比增加14.09%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilk Road Medical, Inc.2024财年第一财季实现净利润-14.14百万美元，同比增加14.09%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-05 00:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405050025458b73c4aa&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月31日，Silk Road Medical, Inc.（SILK.US）公布财报，公告显示公司2024财年第一财季净利润为-14.14百万美元，同比增加14.09%；其中营业收入为48.48百万美元，同比增加20.81%，每股基本收益为-0.36美元。从资产负债表来看，Silk Road Medical, Inc.（SILK.US）总负债1.05亿美元，其中短期债务--，资产负债比为2.40，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405050025458b73c4aa&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SILK","symbol_name":"Silk Road Medical Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405050025458b73c4aa&s=b","article_id":"2433514089","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405050025458b73c4aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2433514089","pubTimestamp":1714839937,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月31日，Silk Road Medical, Inc.公布财报，公告显示公司2024财年第一财季净利润为-14.14百万美元，同比增加14.09%；其中营业收入为48.48百万美元，同比增加20.81%，每股基本收益为-0.36美元。机构评级：截至2024年3月31日，当前有7家机构对Silk Road Medical, Inc.目标价做出预测，其中目标均价为20.71美元，其中最低目标价为8.00美元，最高目标价为28.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"SILK":"Silk Road Medical Inc"},"translate_title":"Silk Road Medical, Inc. achieved net profit in the first quarter of fiscal year 2024-US $14.14 million, a year-on-year increase of 14.09%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SILK":0.9},"content_text":"3月31日，Silk Road Medical, Inc.（SILK.US）公布财报，公告显示公司2024财年第一财季净利润为-14.14百万美元，同比增加14.09%；其中营业收入为48.48百万美元，同比增加20.81%，每股基本收益为-0.36美元。从资产负债表来看，Silk Road Medical, Inc.（SILK.US）总负债1.05亿美元，其中短期债务--，资产负债比为2.40，流动比率为0.12。机构评级：截至2024年3月31日，当前有7家机构对Silk Road Medical, Inc.目标价做出预测，其中目标均价为20.71美元，其中最低目标价为8.00美元，最高目标价为28.00美元。公司简介：Silk Road Medical Inc 是一家专注于降低中风风险及其破坏性影响的医疗设备公司。该公司有一种治疗颈动脉疾病的新方法，称为经颈动脉血管重建术(TCAR)，试图将其建立为治疗标准。TCAR依赖于两个新颖的概念——颈部的微创颈动脉直接通路和手术过程中保护大脑的高速血流逆转——并将新颖的血管内技术与基本的外科原理相结合。TCAR使用其产品组合已被临床证明可以降低颈动脉内膜切除术相关的前期发病率和死亡率风险。该公司的全部收入都来自于美国。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433514089"}